This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions.
Basal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatment can cause scarring. Photodynamic therapy uses light along with a drug applied to the skin to kill the cancer cells and cause them to break apart. The light used can cause the skin to feel warm, but does not cause scarring.

Start Date01 Dec 2024

Sponsor / Collaborator-

NCT06678867 / Not yet recruitingPhase 2IIT

A Phase II Multicentre Trial for the Use of 5-ALA Paediatric Patients with High Grade Brain Tumours

The aim of the study is to examine the safety and feasibility of using 5-ALA in children who have MRI scans showing an aggressive looking brain tumour. It will also study if 5-ALA can help the surgeon achieve maximal tumour removal and discriminate between normal brain tissue and tumour.
Patients will be between 3-18 years (inclusive) and all patients will receive 5-ALA 3-6 hours prior to resection surgery.

Start Date30 Nov 2024

Sponsor / Collaborator

University College London

[+1]

NCT06665724 / Not yet recruitingPhase 1IIT

A Phase 1 Single Center Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined with CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients with Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy

This trial is designed to evaluate safety and explore possible efficacy of 5-aminolevulinic acid hydrochloride (5-ALA HCl, Gliolan®) with CV01 delivery of ultrasound for sonodynamic therapy in patients with newly diagnosed high-grade glioma prior to resection and standard adjuvant therapy.
The study will accrue 10 evaluable high-grade glioma patients. Patients who qualify will receive sonodynamic therapy (5 ALA combined with CV01-delivered sonication) 2 to 5 days prior to standard resection, with one study magnetic resonance imaging being performed between sonodynamic therapy and resection. Resection will be followed by standard radio-/chemotherapy. All patients will be followed up in-study for toxicities and adverse events for 28 days.

Start Date01 Nov 2024

Sponsor / Collaborator

Westfälische Wilhelms-Universität Münster

[+1]

100 Clinical Results associated with Aminolevulinic Acid Hydrochloride

100 Translational Medicine associated with Aminolevulinic Acid Hydrochloride

100 Patents (Medical) associated with Aminolevulinic Acid Hydrochloride

5,172

Literatures (Medical) associated with Aminolevulinic Acid Hydrochloride

01 Feb 2025·Photodiagnosis and Photodynamic Therapy

Efficacy and safety of 5-aminolevulinic acid photodynamic therapy in refractory genital lichen sclerosus

Article

Author: Zhang, Ruzhi ; Chen, Liangliang ; Wang, Fang ; Shi, Weiwei

BACKGROUND:

Genital lichen sclerosus (GLS) is a chronic inflammatory skin disease affecting the genital and anal areas. Treatment of refractory remains a challenge in clinical practice.

OBJECTIVE:

This study aimed to evaluate the efficacy and safety of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) for refractory GLS.

METHODS:

Thirty-five patients with histopathologically confirmed GLS (including 32 females and 3 males) were treated with 5-ALA PDT. Lesion pretreatment was performed to enhance photosensitizer penetration, and fluorescence diagnosis was used for precise point-to-point treatment. Efficacy and safety were systematically evaluated by assessing treatment outcomes, symptom improvement, side effects and maintenance of efficacy over a 6-month follow-up period.

RESULTS:

After treatment, most patients experienced significant relief of pruritus, improved skin elasticity and color, and reduced lesion area. After 6 treatment sessions, 11 patients (31.43 %) achieved complete resolution of pruritus, with 3 patients (8.57 %) achieving complete remission after 3 sessions. Cattaneo scores decreased significantly after treatment and during follow-up (P < 0.05). Adverse reactions were mainly mild pain, which could be relieved by ice compression or oral analgesics.

CONCLUSIONS:

5-ALA PDT shows significant efficacy and good safety for refractory GLS, improving the clinical symptoms and signs of patients, and warrants wider clinical application.

02 Jan 2025·CRITICAL REVIEWS IN BIOTECHNOLOGY

A comprehensive review on the recent advances for 5-aminolevulinic acid production by the engineered bacteria

Review

Author: Wang, Yue-Tong ; Huang, He ; Huang, Jia-Cong ; Yu, Shi-Qin ; Wu, Cai-Yun ; Ye, Chao ; Chen, Ying-Ying ; Shi, Tian-Qiong

5-Aminolevulinic acid (5-ALA) is a non-proteinogenic amino acid essential for synthesizing tetrapyrrole compounds, including heme, chlorophyll, cytochrome, and vitamin B12. As a plant growth regulator, 5-ALA is extensively used in agriculture to enhance crop yield and quality. The complexity and low yield of chemical synthesis methods have led to significant interest in the microbial synthesis of 5-ALA. Advanced strategies, including the: enhancement of precursor and cofactor supply, compartmentalization of key enzymes, product transporters engineering, by-product formation reduction, and biosensor-based dynamic regulation, have been implemented in bacteria for 5-ALA production, significantly advancing its industrialization. This article offers a comprehensive review of recent developments in 5-ALA production using engineered bacteria and presents new insights to propel the field forward.

01 Jan 2025·COLLOIDS AND SURFACES B-BIOINTERFACES

A hyaluronic acid-based dissolving microneedle patch loaded with 5-aminolevulinic acid for improved oral leukoplakia treatment

Article

Author: Sang, Zhiqin ; Hao, Yuanping ; Qu, Xiaoru ; Zhang, Zhe ; Wang, Wanchun ; Zhu, Tingting

INTRODUCTION:

A local microneedle patch loaded with 5-aminolevulinic acid (ALA) was constructed to improve the efficiency of ALA photodynamic treatment of oral leukoplakia, reduce local photosensitivity reactions, and promote the healing of lesions.

METHODS:

The microneedle patch loaded with ALA was constructed with the hyaluronic acid (HA) solution (ALA-HAMN), and its morphology, strength, mucosal penetration, and biocompatibility were tested.

RESULTS:

In vivo safety and permeability tests confirmed that ALA-HAMN had good biocompatibility and could penetrate the mucosal barrier and quickly dissolve and release ALA for in situ transdermal administration. The 4-nitroquinoline oxide (NQO) rat model experiment showed that ALA-HAMN can significantly improve photodynamic therapy (PDT) efficiency and has no damage to mucosal tissue compared with the commonly used ALA cotton ball dressing.

CONCLUSIONS:

The ALA-loaded microneedle patch was successfully constructed for the photodynamic treatment of oral leukoplakia, and the photodynamic efficiency and comfort of oral leukoplakia were improved, which provided an effective delivery mode to improve clinical ALA-PDT treatment of oral leukoplakia (OLK).

News (Medical) associated with Aminolevulinic Acid Hydrochloride

03 Dec 2024

·www.accesswire.com

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced it will be presenting at The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024 at the New York Athletic Club in New York City.The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Biofrontera will be participating in one-on-one meetings with investors and analysts throughout the day.To schedule a one-on-one meeting with Biofrontera, you may submit your request online via the registration link provided. To register for the conference, please visit https://www.meetmax.com/sched/event_112571/investor_reg_new.html?attendee_role_id=INVESTORAbout Biofrontera Inc.Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis (AK), pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate-to-severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/About The Benchmark CompanyThe Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. It was founded in 1988 and are headquartered in New York City. Its focus is on fostering the long-term success of corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm's sales, trading, and equity research capabilities. https://www.benchmarkcompany.com.Contacts Investor RelationsAndrew Barwicki1-516-662-9461[email protected]Forward-Looking StatementsCertain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company's revenue guidance, business and marketing strategy, revenue growth, sales force productivity, growth strategy, liquidity and cash flow, potential to expand the label of Ameluz®, available market opportunities for Ameluz®, ongoing clinical trials, educational outreach efforts, and other statements that are not historical facts. The words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential", "target", "goal", "assume", "would", "could" or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events; nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, our reliance on sales of products we license from other companies as our sole source of revenue; the success of our competitors in developing generic topical dermatological products that successfully compete with our licensed products; the success of our principal licensed product, Ameluz®; the ability of the Company's licensors to establish and maintain relationships with contract manufacturers that are able to supply the Company with enough of the licensed products to meet our demand; the ability of our licensors or their manufacturing partners to supply the licensed products that we market in sufficient quantities and at acceptable quality and cost levels, and to fully comply with current good manufacturing practice or other applicable manufacturing regulations; the ability of our licensors to successfully defend or enforce patents related to our licensed products; the availability of insurance coverage and medical expense reimbursement for our licensed products; the impact of legislative and regulatory changes; competition from other pharmaceutical and medical device companies and existing treatments, such as simple curettage and cryotherapy; the Company's ability to achieve and sustain profitability; the Company's ability to obtain additional financing as needed to implement its growth strategy; the Company's ability to retain and hire key personnel; and other factors that may be disclosed in the Company's filings with the Securities and Exchange Commission ("SEC"), which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not undertake to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release, except as required by law.SOURCE: Biofrontera Inc.

24 Nov 2024

·www.prnewswire.com

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

The results from their first-in-human study demonstrated that median overall survival was doubled and progression-free survival improved 3-fold The Company's novel sonodynamic therapy platform selectively targets and destroys cancer cells in the brain while preserving healthy tissue CHANHASSEN, Minn., Nov. 24, 2024 /PRNewswire/ -- Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced positive results from their Phase 1/2 clinical trial in patients with recurrent or refractory high-grade gliomas. The company's proprietary therapy demonstrated a strong safety profile and extended median overall survival (OS) and progression-free survival (PFS) compared to historical data. The data were presented by Michael Schulder, MD, at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting. "Glioblastomas are the most common and aggressive primary brain cancer, presenting a devasting diagnosis for patients and their familes," said David Reardon, MD, Clinical Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, and member of the Alpheus Medical Scientific Advisory Board. "Current treatment options are limited and often ineffective due to the diffuse spread of the disease across the blood-brain barrier and often across the entire hemisphere, making it universally fatal with a rapid timeline. The early clinical results of Alpheus's therapy are promising, offering hope for this new approach. I look forward to further exploring the potential benefits of their SDT therapy for this patient population who is in critical need of an effective solution." Alpheus Medical's non-invasive SDT treatment, which can be delivered in an outpatient setting, combines low-intensity diffuse ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA) to target and kill cancer cells across the entire hemisphere without the need for imaging or sedation. Key findings from the study include: Median overall survival (OS): 15.7 months vs. historical ~6-8 months Median progression-free survival (PFS): 5.5 months vs. historical 1.8 month Safety: No treatment-related deaths, serious adverse events (SAEs), or duration-limited toxicities (DuLTs) reported "In addition to the strong safety data and early indications of efficacy, Alpheus' non-invasive SDT therapy stands out for its ease of use - a significant improvement over the uncomfortable and often toxic treatments currently available for this rapidly fatal condition," stated Dr. Schulder, Director of the Brain Tumor Center at Northwell Health, and one of the trial's primary investigators. "We look forward to expanding the ability for patients to receive this promising therapy." The Phase 1/2 trial (NCT05362409) is an open-label, multicenter, duration-escalation study evaluating the safety, optimal dose, and efficacy of Alpheus Medical's proprietary SDT platform. Twelve patients were enrolled across three cohorts, with treatment durations escalating to 60, 90, and 120 minutes per monthly session. The company plans to initiate a randomized, controlled trial at multiple centers across the U.S. in 2025. About Alpheus Medical, Inc. Alpheus Medical is a private, clinical-stage oncology company revolutionizing the treatment of solid body cancers with its pioneering sonodynamic therapy (SDT) platform that combines Low-Intensity Diffuse Ultrasound (LIDU™) with the sensitizing agent, oral 5-aminolevulinic acid (5-ALA). The company's proprietary, non-invasive technology is designed to selectively target and destroy cancer cells in the brain while preserving healthy tissue. Learn more at . Media Contact Carla Benigni [email protected] SOURCE Alpheus Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultASCOClinical Study

22 Nov 2024

·www.globenewswire.com

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder’s discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the note will be automatically converted to common shares if the 10-day volume weighted average price (VWAP) of Company shares on Nasdaq is greater than $2.50, and certain other conditions are met. The Notes contain customary restrictive covenants that, among other things, generally limit the ability of the Company to (i) create liens, (ii) pay dividends or acquire shares of capital stock, (iii) incur indebtedness, or (iv) enter into transactions with affiliates. The foregoing restrictive covenants are subject to a number of important exceptions and qualifications, as set forth in the Notes. The proceeds from this financing will primarily support Biofrontera’s general operations and strategic investments, including the Company’s commercial and clinical development initiatives aimed at driving continued sustainable growth. “With our revenues on a steady upward trajectory, the proceeds from this convertible note provide a solid foundation to meet our financial objectives for 2025 and beyond,” said Prof. Hermann Luebbert, CEO of Biofrontera. About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis (AK), pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X. 1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/ Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain statements in this press release constitute “forward-looking statements”. Such statements include estimates of our expenses, future revenue, capital requirements, our need for additional financing, statements regarding the efficacy and intended use of our technologies under development, the timelines and strategy for bringing licensed products to market, the timeline for regulatory review and approval of our licensed products, and other statements that are not historical facts. The words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “target”, “goal”, “assume”, “would”, “could” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should read this press release with the understanding that our actual future results may be materially different from what we expect. While we have based these forward-looking statements on our current expectations and projections about future events, we may not actually achieve the plans, intentions or expectations disclosed in or implied by our forward-looking statements, and you should not place undue reliance on our forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions about us and accordingly, actual results or events could differ materially from the plans, intentions and expectations disclosed in or implied by the forward-looking statements we make. Factors that may cause such differences include, but are not limited to, those identified in Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and our other filings with the SEC. We urge investors and security holders to read those documents free of charge at the SEC’s web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law. Contacts Investor RelationsAndrew Barwicki1-516-662-9461ir@bfri.com

100 Deals associated with Aminolevulinic Acid Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02908	Aminolevulinic Acid Hydrochloride	L01XD04	DB00855

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Carcinoma of urinary bladder, invasive	JP	SBI Pharmaceuticals Co., Ltd.	27 Sep 2017
Glioblastoma Multiforme	AU	Specialised Therapeutics Glio Pty Ltd	07 Nov 2013
Contrast agents	JP	Nobelpharma Co., Ltd.	25 Mar 2013
Basal Cell Carcinoma	EU	Biofrontera Bioscience GmbH	13 Dec 2011
Basal Cell Carcinoma	IS	Biofrontera Bioscience GmbH	13 Dec 2011
Basal Cell Carcinoma	LI	Biofrontera Bioscience GmbH	13 Dec 2011
Basal Cell Carcinoma	NO	Biofrontera Bioscience GmbH	13 Dec 2011
Glioma	EU	Photonamic GmbH & Co. KG	07 Sep 2007
Glioma	IS	Photonamic GmbH & Co. KG	07 Sep 2007
Glioma	LI	Photonamic GmbH & Co. KG	07 Sep 2007
Glioma	NO	Photonamic GmbH & Co. KG	07 Sep 2007
Condylomata Acuminata	CN	Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.	14 Feb 2007
Actinic Keratosis	US	DUSA Pharmaceuticals, Inc.	03 Dec 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Epithelial Carcinoma	Phase 3	US	NX Development Corp.	30 May 2024
Recurrent ovarian cancer	Phase 3	US	NX Development Corp.	30 May 2024
Breast Cancer	Phase 3	US	Sbi Alapharma Canada, Inc.	27 Apr 2021
Carcinoma	Phase 3	US	Sbi Alapharma Canada, Inc.	27 Apr 2021
Meningioma	Phase 3	US	NX Development Corp.	28 Oct 2020
Meningioma	Phase 3	AT	NX Development Corp.	28 Oct 2020
Meningioma	Phase 3	DE	NX Development Corp.	28 Oct 2020
Superficial basal cell carcinoma	Phase 3	US	Biofrontera Bioscience GmbH	25 Sep 2018
Malignant glioma of brain	Phase 3	JP	Nobelpharma Co., Ltd.	01 Aug 2010
Recurrent Malignant Glioma	Phase 3	JP	Nobelpharma Co., Ltd.	01 Aug 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01128218 (Phase 2 Sensitivity and Selectivity Study, Pubmed \| Oper Neurosurg (Hagerstown))	Phase 2	Recurrent Glioblastoma	31	High-dose 5-ALA (>40 mg/kg)	qbhbtzddzt(kxleojsqew) = tunljedhbs kpofthfghk (kvpnsuxsan ) View more	Positive	11 Nov 2024
				Low/standard dose 5-ALA (<30 mg/kg)	qbhbtzddzt(kxleojsqew) = ftunbgfpqo kpofthfghk (kvpnsuxsan ) View more
TMOD-04 (SNO2024)	Phase 1	-	8	Sonodynamic Therapy with 5-ALA HCL Oral Solution and CV-01	fqvgqndwcy(vnamdzrnfi) = owchorznjf umcfftbhzf (vsnzvmeenh )	Positive	11 Nov 2024
				5-ALA HCL oral solution (Control Group)	fqvgqndwcy(vnamdzrnfi) = lgsfrjqqxi umcfftbhzf (vsnzvmeenh )
NCT03573401 (ALA-BCC-CT013, GlobeNewswire) Manual	Phase 3	Basal Cell Carcinoma	187	Ameluz®-PDT	ugoehqrmwu(bikoilftun) = gevxceefqm owjemhirml (bzajedosoo ) View more	Positive	31 Oct 2024
				Placebo-PDT	ugoehqrmwu(bikoilftun) = blcbajswji owjemhirml (bzajedosoo ) View more
P18.53.A (EANO2024)	Not Applicable	Glioblastoma Adjuvant 5-aminolevulinic acid (5-ALA) positive	23	5-aminolevulinic acid (5-ALA) (No residual 5-ALA)	hoypwdlbvr(zlgtcvuamz) = fsasdvokqn fuittbzzvt (uvwmwwrxgm ) View more	Negative	17 Oct 2024
				5-aminolevulinic acid (5-ALA) (Focal residual 5-ALA)	hoypwdlbvr(zlgtcvuamz) = lgoxjfmwug fuittbzzvt (uvwmwwrxgm ) View more
P10.22.B (EANO2024)	Not Applicable	Glioma	163	5-ALA (Fluorescent Gliomas)	xiwkxrstwl(gfvdbtxdgy) = zonwjddgci lujvbljdav (rajgijohdt ) View more	Positive	17 Oct 2024
NCT03048240 (INDYGO, Pubmed \| J Neurooncol)	Not Applicable	Glioblastoma 5-aminolevulinic acid hydrochloride (5-ALA HCl)	-	Intraoperative photodynamic therapy (PDT) with 5-aminolevulinic acid hydrochloride (5-ALA HCl)	okwllvefcb(bwicssybqw) = jdterhjwmd gitjyusadj (vpimdzbzqq ) View more	Positive	01 Jul 2024
NCT03327831 (CTgov)	Phase 4	Actinic Keratosis	30	Aminolevulinic Acid	pwhhrranol(ggemvfdzpd) = jozeftqkke qmrvvhingp (dyisrxhuhv, zueqcnqzla - qrigzgqiia) View more	-	27 Jun 2024
MP77-20 (AUA2024)	Not Applicable	Non-Muscle Invasive Bladder Neoplasms	33	Fluorescence cystoscopy using oral 5-aminolevulinic acid (ALA)	nsldajyujf(youeluvwsc) = dhwqmytemx cfqqfyhjaa (uupgjvbzpb ) View more	Positive	01 May 2024
				5-aminolevulinic acid (White-light endoscopy)	nsldajyujf(youeluvwsc) = rsaktxzzhg cfqqfyhjaa (uupgjvbzpb ) View more
PD30-02 (AUA2024)	Not Applicable	Bladder Cancer	302	Fluorescence cystoscopy using oral 5-aminolevulinic acid (ALA)	yjkdcerckm(qexlovdwri) = gqdbuezqlz ycvxyrjotg (mptttdnqiw ) View more	Negative	01 May 2024
				5-AMINOLEVULINIC ACID (White light cystoscopy)	yjkdcerckm(qexlovdwri) = khxhnxhbog ycvxyrjotg (mptttdnqiw ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis